Incannex Healthcare Inc. (IXHL)
NASDAQ: IXHLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IXHL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $23.34M
- EPS (TTM)
- -$1.25
- Dividend yield
- None
- 52-week range
- 1.61 – 14.91
- Day range
- 1.69 – 1.99
- Volume / Avg
- 219.82K / 91.61K
- Beta
- —
- Shares outstanding
- 12.55M
52-week range
IXHL stock today
Incannex Healthcare (IXHL) closed at $1.86 on Nov 20, up 6.90% (+$0.12), versus the S&P 500's 3.70% decline. Volume was 2.4x the average at 219.82K shares, a sign of unusually heavy trading. Shares are 87.5% below their 52-week high of $14.91, set on Dec 4, 2025 and 15.5% above the 52-week low of $1.61, near the bottom of the past year's range.
IXHL is down 82.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 80.3%. Incannex Healthcare has posted a net loss over the last twelve months (EPS of -$1.25), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Incannex Healthcare
Company profileIncannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Joel Bradley Latham
- Headquarters
- Melbourne, VIC
- Employees
- 12
- Website
- incannex.com
Financial highlights
Full financialsIn fiscal 2026, Incannex Healthcare generated $0 in revenue, down 100.0% from fiscal 2025, the first decline in the 7 years shown. Incannex Healthcare reported a net loss of $19.3 million, compared with a loss of $46.9 million a year earlier. Diluted earnings per share came in at -$1.66.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $86.00K | $12.00K | — | — |
| Growth | -100.00% | +616.67% | — | — | — |
| Net income | $-19.30M | $-46.88M | $-18.46M | $-48.81M | $-14.90M |
| EPS (diluted) | $-1.66 | $-40.82 | $-1.15 | $-3.32 | $-1.25 |
Analyst forecast
ForecastConsensus (1 analysts)
strong_buy
Avg. price target
$18.68+904.30%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.15 vs $-0.66
- Surprise
- +77.27%
Incannex Healthcare peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ABVCABVC BioPharma Inc. | 0.8663 | -1.56% | $23.37M | vs IXHL |
| RMTIRockwell Medical Inc. | 5.82 | -7.03% | $23.12M | vs IXHL |
| SCYXSCYNEXIS Inc. | 2.38 | -8.64% | $23.69M | vs IXHL |
| IMMPImmutep Limited ADR | 3.11 | -9.06% | $22.92M | vs IXHL |
| LITSLite Strategy Inc. | 0.8026 | -4.03% | $23.99M | vs IXHL |
| CRVOCervoMed Inc. | 1.46 | +9.77% | $22.09M | vs IXHL |
| AARDAardvark Therapeutics Inc. | 0.9226 | -7.74% | $20.20M | vs IXHL |
| RNAZTransCode Therapeutics Inc. | 1.16 | -10.77% | $20.07M | vs IXHL |
Indexes, lists and sector
Incannex Healthcare stock FAQ
What is Incannex Healthcare's stock price today?
IXHL last traded at $1.86 as of Nov 20, 4:00 PM EST, up 6.90% on the day. Prices are delayed at least 15 minutes.
Does Incannex Healthcare pay a dividend?
No. Incannex Healthcare does not currently pay a regular cash dividend.
Who is Incannex Healthcare's CEO?
Mr. Joel Bradley Latham is the chief executive officer of Incannex Healthcare Inc., which has about 12 employees.
Has IXHL ever split its stock?
Yes. The most recent IXHL stock split was a 1-for-30 split on Feb 27, 2026.
What is the IXHL 52-week high?
The 52-week high for IXHL is $14.91 and the 52-week low is $1.61. The stock is currently 87.5% below its high.